GeoVax Labs, Inc. will report financial results for the quarter ended September 30, 2025, after market close on November 13, 2025. Management will host a conference call and webcast at 4:30 p.m. ET to review results and provide a business update, offering investors crucial insights into the company's financial health and clinical progress.
The company's lead clinical program, GEO-CM04S1, represents a next-generation COVID-19 vaccine currently undergoing three Phase 2 clinical trials. These trials evaluate the vaccine as a primary option for immunocompromised patients, including those with hematologic cancers who respond inadequately to current authorized vaccines. Additional studies examine GEO-CM04S1 as a booster for chronic lymphocytic leukemia patients and as a more robust, durable COVID-19 booster for healthy individuals previously vaccinated with mRNA vaccines.
In oncology, GeoVax's lead program focuses on Gedeptin®, a novel oncolytic solid tumor gene-directed therapy that recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. The company also develops a vaccine targeting Mpox and smallpox, which based on recent European Medicines Agency regulatory guidance, may progress directly to Phase 3 clinical evaluation, bypassing earlier trial phases.
Investors can access the live audio webcast through the Company's Investor Relations website or register for the conference call using the provided registration link. The webcast archive will be available approximately two hours after the call concludes and remain accessible for at least 90 days, allowing investors who miss the live presentation to review the information at their convenience.
The upcoming financial report and corporate update hold significance for stakeholders monitoring GeoVax's progress in developing innovative vaccine technologies. The company maintains worldwide rights for its technologies and products, supported by a strong intellectual property portfolio. For business leaders and investors tracking advancements in biotechnology, GeoVax's progress represents potential breakthroughs in addressing unmet medical needs across infectious diseases and oncology.
The company's approach to COVID-19 vaccination for immunocompromised populations addresses a critical gap in current vaccine strategies, potentially offering protection to vulnerable patient groups who remain at high risk despite existing vaccination options. Similarly, the accelerated development pathway for the Mpox vaccine could position GeoVax as a key player in global preparedness for orthopoxvirus threats.
GeoVax's oncology program with Gedeptin® demonstrates the company's expansion beyond infectious diseases into cancer therapeutics, representing diversification that could enhance long-term value creation. The combination of multiple clinical-stage assets across different therapeutic areas provides investors with multiple catalysts for potential growth and market differentiation in the competitive biotechnology landscape.
